Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
38.069,95 +441,47 (+1,17%) EUR/USD
1,0724 -0,0009 (-0,09%) Bitcoin EUR
60.074,04 +77,27 (+0,13%) CMC Crypto 200
1.390,19 +7,62 (+0,55%)
COMPASS Pathways plc (CMPS)
Dopo ore:
| Chiusura precedente | 8,10 |
| Aperto | 8,10 |
| Denaro | 7,83 x 100 |
| Lettera | 7,88 x 100 |
| Min-Max giorno | 7,64 - 8,10 |
| Intervallo di 52 settimane | 5,01 - 12,75 |
| Volume | |
| Media Volume | 702.429 |
| Capitalizzazione | 553,574M |
| Beta (5 anni mensile) | 2,48 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,25 |
| Prossima data utili | 06 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 41,25 |
GlobeNewswireCOMPASS Pathways appoints Daphne Karydas to its Board of Directors
LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for c
- GlobeNewswire
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a new paper in Pyschopharmacology, which showed the results of a retrospective study that evaluates the potential of its AI technologies to support investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The paper was published on
- GlobeNewswire
COMPASS Pathways to participate in upcoming September investor conferences
LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following investor conferences: Citi’s 18th Annual BioPharma Conference: host investor meetings on September 7, 2023HC Wainwright 25th Annual Global Investment Conference: fireside chat at 3:30pm on September 11, 2023 and host investor meetingsMorgan St
